Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ADCT

Adc Therapeutics SA

Sep 20 • 04:00PM ET

3.33

Dollar change +0.12
Percentage change 3.74	%

Healthcare • Biotechnology • Switzerland • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM IWO IWN VTWO IWC RSSL VTWG GSSC VTWV FESM

Index	RUT	P/E	-	EPS (ttm)	-2.56	Insider Own	19.19%	Shs Outstand	82.29M	Perf Week	7.42%
Market Cap	321.91M	Forward P/E	-	EPS next Y	-1.45	Insider Trans	4.14%	Shs Float	78.12M	Perf Month	13.27%
Income	-215.99M	PEG	-	EPS next Q	-0.38	Inst Own	67.51%	Short Float	3.47%	Perf Quarter	25.66%
Sales	66.75M	P/S	4.82	EPS this Y	42.66%	Inst Trans	4.63%	Short Ratio	4.51	Perf Half Y	-27.77%
Book/sh	-1.36	P/B	-	EPS next Y	13.73%	ROA	-49.14%	Short Interest	2.71M	Perf Year	333.59%
Cash/sh	3.10	P/C	1.07	EPS next 5Y	15.80%	ROE	-705.53%	52W Range	0.36 - 6.04	Perf YTD	100.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	84.52%	ROI	-	52W High	-44.87%	Beta	1.58
Dividend TTM	-	Quick Ratio	5.90	Sales past 5Y	91.46%	Gross Margin	92.13%	52W Low	825.24%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	6.17	EPS Y/Y TTM	-13.36%	Oper. Margin	-207.40%	RSI (14)	62.22	Volatility	6.20% 7.36%
Employees	162	Debt/Eq	-	Sales Y/Y TTM	-63.80%	Profit Margin	-323.60%	Recom	1.43	Target Price	9.80
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	33.96%	Payout	-	Rel Volume	3.13	Prev Close	3.21
Sales Surprise	-7.81%	EPS Surprise	16.89%	Sales Q/Q	-9.71%	Earnings	Aug 06 BMO	Avg Volume	601.94K	Price	3.33
SMA20	12.65%	SMA50	5.91%	SMA200	-2.24%	Trades		Volume	1,886,539	Change	3.74%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Sep-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -5.86%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:40AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -7.83% -5.88%
07:15AM	Loading…
Jul-30-24 07:15AM	ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024 (GlobeNewswire)
Jul-11-24 03:24PM	7 Growth Stocks to Buy for Under $5 for Massive Gains (InvestorPlace) +20.32%
Jul-08-24 02:00AM	Myricx Bio Announces 90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development (GlobeNewswire) -6.13%
Jul-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +16.46% -5.43%
Jun-27-24 07:15AM	ADC Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-13-24 02:31PM	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget (InvestorPlace)
Jun-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +5.74%
May-30-24 07:15AM	ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 07:15AM	ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-09-24 07:01PM	Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT) (GuruFocus.com) -5.91%
07:15AM	Loading…
07:15AM	ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 08:55AM	ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.54%
08:44AM	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating (MT Newswires)
May-06-24 10:53AM	ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -9.18%
08:22AM	ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell (MT Newswires)
07:30AM	ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
07:20AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:55AM	ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial (MT Newswires)
06:10AM	ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
06:00AM	ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma (GlobeNewswire)
May-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +6.80%
07:00AM	ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 (GlobeNewswire)
Apr-16-24 08:30AM	ADC Therapeutics Accelerates R&D with Genedata Biologics (PR Newswire)
Apr-04-24 07:00AM	ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +6.32%
Apr-03-24 07:00AM	ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 (GlobeNewswire)
04:05PM	Loading…
Apr-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
Mar-15-24 12:30PM	ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 05:16AM	Q4 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:51AM	ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset (GuruFocus.com) -12.36%
08:20AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-24 07:15AM	ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit (GlobeNewswire)
07:00AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 (GlobeNewswire)
Mar-05-24 05:45PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-27-24 07:00AM	ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline (Zacks) -8.88%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey) +6.44%
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-19-24 01:05PM	ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why (Zacks)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-04-24 10:05AM	ADC Therapeutics, Aldeyra start off New Year with program discontinuations (FierceBiotech.com) +13.25%
07:15AM	ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Provides Business Updates (GlobeNewswire)
Dec-12-23 05:15AM	ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (GlobeNewswire)
Nov-20-23 02:40AM	Sobi to present new data at ASH 2023 Annual Meeting (PR Newswire)
Nov-15-23 03:00AM	Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors (GlobeNewswire) +6.15%
Nov-08-23 01:26PM	ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript (Insider Monkey) -17.26%
01:03AM	Q3 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:15AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -15.97%
07:15AM	ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-23 07:00AM	ADC Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +7.87%
Nov-02-23 05:50PM	Puma Biotech (PBYI) Tops Q3 Earnings Estimates (Zacks) +14.27%
10:10AM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting (GlobeNewswire)
Nov-01-23 10:01AM	Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-31-23 10:01AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-24-23 07:00AM	ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023 (GlobeNewswire)
Oct-04-23 04:00AM	Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO (GlobeNewswire)
Sep-05-23 07:00AM	ADC Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -7.38%
Aug-30-23 07:33PM	ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) (GlobeNewswire)
Aug-14-23 10:51AM	Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% (Zacks)
Aug-11-23 10:53AM	Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised (Zacks)
Aug-10-23 10:31AM	Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up (Zacks) +7.33%
Aug-09-23 12:09PM	Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales (Zacks) -6.25%
Aug-08-23 11:01PM	Q2 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents) +11.89%
10:48AM	Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates (Zacks)
08:15AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-07-23 05:25PM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-23 08:40AM	Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised (Zacks)
08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Aug-03-23 11:48AM	Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View (Zacks)
11:45AM	Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus (Zacks)
08:02AM	Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up (Zacks)
Aug-02-23 12:45PM	Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated (Zacks)
12:42PM	Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-01-23 10:45AM	Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues (Zacks)
07:22AM	Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 27%? (Simply Wall St.)
07:00AM	ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 (GlobeNewswire)
Jul-28-23 08:02AM	Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates (Zacks)
Jul-26-23 08:52AM	Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results (Zacks)
Jul-24-23 01:20PM	Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche (Zacks) -7.75%
11:12AM	Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study (Zacks)
07:21AM	Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (GlobeNewswire)
Jul-21-23 01:22PM	GSK Gears Up for Q2 Earnings: Will It Surpass Estimates? (Zacks) -5.33%
07:44AM	Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug (Zacks)
Jul-20-23 04:05PM	ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients (GlobeNewswire)
Jul-19-23 09:59AM	Adial (ADIL) Shares Up 43% in the Past Week: Here's Why (Zacks)
Jul-18-23 11:04AM	Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets (Zacks)
Jul-17-23 10:59AM	Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study (Zacks)
10:06AM	Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study (Zacks)
Jul-14-23 10:56AM	Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study (Zacks)
09:55AM	ADC Therapeutics SA (ADCT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
08:03AM	Acadia (ACAD) Expands Existing Licensing Deal With Neuren (Zacks)

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Redmile Group, LLC	10% Owner	Jul 01 '24	Buy	2.81	400,000	1,124,000	15,669,217	Jul 03 08:00 PM
Redmile Group, LLC	10% Owner	Jul 01 '24	Buy	2.81	400,000	1,124,000	12,995,040	Jul 03 08:00 PM
Azelby Robert	Director	Jun 17 '24	Sale	2.89	6,995	20,216	53,005	Jun 18 09:45 PM
BIZZARI JEAN-PIERRE	Director	Jun 17 '24	Sale	2.89	6,995	20,216	79,502	Jun 18 09:43 PM
Hug Peter	Director	Jun 17 '24	Sale	2.89	1,193	3,448	182,644	Jun 18 09:41 PM
Monges Viviane	Director	Jun 17 '24	Sale	2.89	1,437	4,153	106,627	Jun 18 09:40 PM
Pfisterer Thomas	Director	Jun 17 '24	Sale	2.89	1,437	4,153	213,900	Jun 18 09:38 PM
Sandor Victor	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,886	Jun 18 09:37 PM
Squarer Ron	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,663	Jun 18 09:35 PM
MALLIK AMEET	Chief Executive Officer	May 07 '24	Sale	4.48	29,731	133,195	1,167,348	May 09 04:06 PM

Open in Screener

ABSI

Absci Corp

Sep 20 • 04:00PM ET

4.32

Dollar change +0.01
Percentage change 0.23	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: ARKG VTI IWM VXF IWO SCHA VTWO IWN DFAC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	19.41%	Shs Outstand	93.09M	Perf Week	10.77%
Market Cap	490.58M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	-12.40%	Shs Float	91.51M	Perf Month	-0.69%
Income	-92.26M	PEG	-	EPS next Q	-0.19	Inst Own	58.43%	Short Float	13.20%	Perf Quarter	43.05%
Sales	3.25M	P/S	150.95	EPS this Y	35.83%	Inst Trans	3.14%	Short Ratio	8.20	Perf Half Y	-18.18%
Book/sh	1.95	P/B	2.21	EPS next Y	15.58%	ROA	-36.20%	Short Interest	12.08M	Perf Year	184.21%
Cash/sh	1.42	P/C	3.03	EPS next 5Y	23.30%	ROE	-42.24%	52W Range	1.11 - 6.72	Perf YTD	2.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.78%	ROI	-40.14%	52W High	-35.71%	Beta	2.21
Dividend TTM	-	Quick Ratio	6.49	Sales past 5Y	37.94%	Gross Margin	-324.52%	52W Low	288.80%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	6.49	EPS Y/Y TTM	23.61%	Oper. Margin	-3008.03%	RSI (14)	58.11	Volatility	6.51% 7.01%
Employees	156	Debt/Eq	0.06	Sales Y/Y TTM	-62.04%	Profit Margin	-2838.89%	Recom	1.29	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	51.70%	Payout	-	Rel Volume	1.15	Prev Close	4.31
Sales Surprise	-33.41%	EPS Surprise	-21.28%	Sales Q/Q	-62.28%	Earnings	Aug 14 AMC	Avg Volume	1.47M	Price	4.32
SMA20	6.04%	SMA50	6.11%	SMA200	1.60%	Trades		Volume	1,691,697	Change	0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-24	Initiated	Morgan Stanley	Overweight	$7
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$3
May-04-23	Initiated	H.C. Wainwright	Buy	$4
Aug-12-22	Downgrade	JP Morgan	Overweight → Underweight
Jul-18-22	Initiated	Truist	Buy	$8
Mar-02-22	Resumed	Cowen	Market Perform
Feb-01-22	Initiated	Berenberg	Buy	$28
Nov-10-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Oct-15-21	Resumed	Cowen	Market Perform
Aug-16-21	Initiated	Stifel	Hold	$28
Aug-16-21	Initiated	Credit Suisse	Outperform	$40
Aug-16-21	Initiated	Cowen	Market Perform
Aug-16-21	Initiated	BofA Securities	Neutral	$26

Show Previous Ratings

Aug-31-24 02:37PM	Absci Corporation (ABSI): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-30-24 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Aug-21-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 05:30PM	Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +10.99%
04:01PM	Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
08:00AM	Loading…
Aug-12-24 08:00AM	Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI (GlobeNewswire)
Jul-31-24 04:25AM	Why Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now? (Insider Monkey)
Jul-10-24 08:00AM	Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 (GlobeNewswire)
Jul-03-24 04:00PM	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.07%
Jun-21-24 11:08AM	Is Absci Corporation (NASDAQ:ABSCI) the Best Halal Stock According to Hedge Funds? (Insider Monkey)
Jun-12-24 08:00AM	Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit (GlobeNewswire) +9.98%
May-28-24 08:00AM	Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
May-16-24 07:15AM	7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs (InvestorPlace)
May-15-24 03:01AM	Absci Corp (ABSI) Q1 2024 Earnings Call Transcript Highlights: Strategic Advancements and ... (GuruFocus.com)
11:53AM	Loading…
May-14-24 11:53AM	ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:30AM	Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-07-24 09:13AM	Absci (ABSI) to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-16-24 08:00AM	Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024 (GlobeNewswire)
Apr-10-24 11:07AM	Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last? (Zacks) -7.67%
Mar-28-24 04:05PM	Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-24 05:31AM	Absci Corp (ABSI) Earnings: Misses Revenue Estimates and Reports Increased Net Loss (GuruFocus.com)
Mar-21-24 02:52PM	ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:30AM	Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results (GlobeNewswire)
Mar-12-24 05:34PM	11 Stocks Insiders are Buying Now (Insider Monkey) +5.11%
Mar-06-24 06:34AM	Latest Updates of Viva Biotech's Portfolio Companies (PR Newswire)
Mar-01-24 04:01PM	Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +5.81% +5.13%
06:49AM	Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains? (Zacks)
Feb-27-24 10:20PM	Absci Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Loading…
04:01PM	Absci Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-21-24 07:30AM	Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI (GlobeNewswire)
Feb-20-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.76%
Feb-05-24 09:40AM	Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year? (Zacks) -9.93%
Jan-10-24 07:30AM	Absci Appoints Professor Sir Mene Pangalos to its Board of Directors (GlobeNewswire) +7.06%
Jan-08-24 07:00AM	Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +15.47%
Jan-03-24 08:00AM	Absci to Participate in the 26th Annual Needham Growth Conference (GlobeNewswire)
Dec-28-23 08:00AM	Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 07:30AM	Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline (GlobeNewswire)
Dec-05-23 08:11AM	Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy (Zacks) +8.16%
Dec-04-23 07:30AM	Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate (GlobeNewswire) +12.64%
06:18AM	AstraZeneca inks $247M, AI-enabled oncology antibody design pact, joining Absci's list of pharma allies (FierceBiotech.com)
Dec-03-23 01:27AM	AstraZeneca, AI biologics firm Absci tie up on cancer drug (Reuters)
01:22AM	UPDATE 2-AstraZeneca, AI biologics firm Absci tie up on cancer drug (Reuters)
12:21AM	AstraZeneca ties up with AI biologics company to develop cancer drug - FT (Reuters)
12:00AM	AstraZeneca ties up with AI biologics company to develop cancer drug (Financial Times)
Nov-15-23 08:00AM	Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 06:15PM	Absci Corp (ABSI) Reports Decrease in Q3 Revenue and Lower Net Loss Year-Over-Year (GuruFocus.com) +12.00%
04:05PM	Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
02:16AM	Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases (Business Wire)
Oct-26-23 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-21-23 08:00AM	Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen (GlobeNewswire)
Sep-06-23 08:00AM	Absci to Host R&D Day on October 4, 2023 (GlobeNewswire)
Aug-28-23 04:05PM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.82%
Aug-14-23 03:51PM	The 3 Most Undervalued Penny Stocks to Buy Now: August 2023 (InvestorPlace) +5.36%
08:02AM	Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results (GlobeNewswire)
08:00AM	Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
Aug-10-23 08:00AM	Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development (GlobeNewswire)
Aug-01-23 08:00AM	Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023 (GlobeNewswire) -7.27%
Jul-26-23 08:00AM	Absci to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-15-23 08:00AM	Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit (GlobeNewswire)
Jun-07-23 09:32AM	Shareholders in Absci (NASDAQ:ABSI) are in the red if they invested a year ago (Simply Wall St.)
Jun-06-23 08:00AM	Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips (GlobeNewswire)
May-15-23 05:45PM	Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.59%
04:05PM	Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results (GlobeNewswire)
May-11-23 08:00AM	University of Oxfords Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies (GlobeNewswire) -5.34%
May-03-23 10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-06-23 08:00AM	Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-04-23 08:00AM	Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology (GlobeNewswire)
Apr-01-23 08:25AM	Absci Full Year 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Mar-30-23 04:05PM	Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results (GlobeNewswire)
Mar-23-23 08:00AM	Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation (GlobeNewswire)
Mar-07-23 08:00AM	Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
06:08AM	Absci Corporation (NASDAQ:ABSI) has caught the attention of institutional investors who hold a sizeable 29% stake (Simply Wall St.)
Feb-28-23 08:00AM	Absci Expands in Europe with Launch of New Innovation Center and Additional Senior Leadership in Switzerland (GlobeNewswire)
Feb-21-23 08:00AM	Absci to Participate in the 43rd Annual Cowen Health Care Conference (GlobeNewswire) -8.99%
Feb-09-23 08:00AM	St. Johns Cancer Institute Partners with Absci to Expedite Development of Cancer Therapies (GlobeNewswire) -5.08%
Feb-08-23 08:00AM	Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation (GlobeNewswire) -9.23%
Jan-10-23 10:36AM	10 Penny Stocks That Will Make You A Millionaire (Insider Monkey) +5.35%
10:00AM	Absci announces AI breakthrough in designing therapeutic antibodies (American City Business Journals)
08:00AM	Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI (GlobeNewswire)
Jan-08-23 03:13PM	Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-22 07:17AM	Absci (NASDAQ:ABSI) shareholders have endured a 76% loss from investing in the stock a year ago (Simply Wall St.) +7.18%
Dec-28-22 08:00AM	Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-23-22 08:00AM	Absci to Participate in the Berenberg Discover AI Seminar (GlobeNewswire)
Nov-17-22 08:00AM	Absci to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire) -8.55%
Nov-09-22 10:47AM	Absci reports $27M loss but strong cash position (American City Business Journals)
09:15AM	Absci Corporation (ABSI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Absci Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 04:05PM	Absci to Participate in the Stifel Healthcare Conference (GlobeNewswire) -5.81%
08:00AM	Absci Welcomes Meta Senior Executive to Board of Directors (GlobeNewswire)
Oct-26-22 08:00AM	Absci to Participate in the 31st Annual Credit Suisse Healthcare Conference (GlobeNewswire)
Oct-04-22 07:00AM	Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer (GlobeNewswire) +10.10%
Sep-28-22 06:44AM	Institutional owners may consider drastic measures as Absci Corporation's (NASDAQ:ABSI) recent US$46m drop adds to long-term losses (Simply Wall St.) +7.21%
Sep-01-22 08:00AM	Absci to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire) +6.82%
Aug-24-22 07:00AM	Absci to Participate at the Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-15-22 04:00PM	Absci analysts mostly bullish after Q2 earnings, 'prudent' layoffs (American City Business Journals) -5.18%
Aug-11-22 09:15AM	Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +14.05%
08:00AM	Absci Reports Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Aug-10-22 10:50AM	Vancouver biotech firm Absci lays off employees, cites economy (American City Business Journals) +7.69%

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Option Exercise	3.39	28,700	97,293	404,610	Jun 14 04:40 PM
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Sale	4.98	19,859	98,892	384,751	Jun 14 04:40 PM
Phoenix Venture Partners II LP	10% Owner	May 22 '24	Sale	4.40	3,100,000	13,640,000	11,279,522	May 28 01:56 PM
Redmile Group, LLC	Director	Mar 01 '24	Buy	4.50	222,222	999,999	8,253,316	Mar 05 09:30 PM

Open in Screener

FATE

Fate Therapeutics Inc

Sep 20 • 04:00PM ET

3.87

Dollar change -0.13
Percentage change -3.25	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

FATE Fate Therapeutics Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWN KOMP DFAT SCHA VTWO DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.71	Insider Own	16.69%	Shs Outstand	98.63M	Perf Week	-3.73%
Market Cap	440.72M	Forward P/E	-	EPS next Y	-1.65	Insider Trans	-0.00%	Shs Float	94.87M	Perf Month	-1.02%
Income	-175.72M	PEG	-	EPS next Q	-0.42	Inst Own	93.17%	Short Float	15.99%	Perf Quarter	2.93%
Sales	12.32M	P/S	35.77	EPS this Y	-0.05%	Inst Trans	-2.38%	Short Ratio	8.53	Perf Half Y	-47.91%
Book/sh	3.49	P/B	1.11	EPS next Y	-0.81%	ROA	-31.56%	Short Interest	15.17M	Perf Year	72.00%
Cash/sh	2.68	P/C	1.45	EPS next 5Y	-	ROE	-42.10%	52W Range	1.63 - 8.83	Perf YTD	3.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.65%	ROI	-35.80%	52W High	-56.17%	Beta	1.84
Dividend TTM	-	Quick Ratio	9.18	Sales past 5Y	87.14%	Gross Margin	-55.61%	52W Low	137.42%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	9.18	EPS Y/Y TTM	21.30%	Oper. Margin	-1587.28%	RSI (14)	51.54	Volatility	7.07% 7.58%
Employees	181	Debt/Eq	0.25	Sales Y/Y TTM	-89.67%	Profit Margin	-1426.67%	Recom	2.65	Target Price	6.62
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	38.99%	Payout	-	Rel Volume	1.42	Prev Close	4.00
Sales Surprise	410.52%	EPS Surprise	28.80%	Sales Q/Q	625.83%	Earnings	Aug 13 AMC	Avg Volume	1.78M	Price	3.87
SMA20	3.95%	SMA50	-4.15%	SMA200	-17.13%	Trades		Volume	2,529,331	Change	-3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50 → $47
Jun-03-22	Initiated	Robert W. Baird	Neutral	$28
Feb-11-22	Resumed	BMO Capital Markets	Market Perform	$50

Show Previous Ratings

Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.12% -9.50%
Jul-31-24 08:00AM	Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors (GlobeNewswire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:01PM	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 10:48AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 02:50PM	Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ... (GuruFocus.com)
10:36AM	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating (MT Newswires)
08:22AM	Loading…
08:22AM	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating (MT Newswires)
May-09-24 08:58PM	FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.41%
05:25PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
08:30AM	Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program (GlobeNewswire)
May-06-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting (GlobeNewswire)
Apr-22-24 04:30PM	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting (GlobeNewswire) -5.02%
Apr-06-24 02:17AM	Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress (Zacks)
Apr-04-24 11:30PM	NOTICE TO LONG-TERM SHAREHOLDERS OF FATE THERAPEUTICS, INC. (FATE): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF (Newsfile)
Apr-03-24 08:00AM	Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-24 11:30AM	Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks) +7.00%
Mar-19-24 08:44AM	Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement (GlobeNewswire)
04:01PM	Loading…
Mar-05-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15%
Mar-01-24 08:09AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.17%
08:00AM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-27-24 09:16AM	Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y (Zacks) +7.34%
08:07AM	Q4 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
04:08PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-19-24 10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-15-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.09%
Feb-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-24 07:54AM	Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-24 02:53PM	Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock (InvestorPlace) +25.44%
Jan-08-24 08:00AM	Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors (GlobeNewswire) +9.28%
Dec-22-23 12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's Why (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 05:00PM	Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.67% +11.19%
Dec-08-23 11:30AM	Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 01:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.58%
Nov-08-23 06:18PM	Fate Therapeutics Inc (FATE) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:08PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Oct-25-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results (GlobeNewswire) -7.22%
Sep-15-23 06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks) -6.78%
Sep-07-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report? (Zacks)
Aug-31-23 08:00AM	Fate Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-09-23 12:12PM	FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss (Zacks)
11:04AM	Q2 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:11PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jul-28-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-22-23 08:35AM	One Fate Therapeutics Insider Raised Stake By 83% In Previous Year (Simply Wall St.)
Jul-01-23 10:33AM	We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-16-23 03:53PM	Why Shares of Fate Therapeutics Soared This Week (Motley Fool)
Jun-14-23 06:42AM	Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains? (Zacks)
Jun-08-23 11:30AM	Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-07-23 11:30AM	Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report? (Zacks)
Jun-04-23 08:27AM	Fate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For Excitement (Simply Wall St.)
Jun-02-23 11:31AM	Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-23 08:00AM	Fate Therapeutics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey) -5.62%
May-08-23 06:05AM	Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher (Simply Wall St.)
May-04-23 11:59AM	FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses (Zacks)
11:22AM	Q1 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.76%
04:11PM	Fate Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-27-23 10:03AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-26-23 10:02AM	Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results (GlobeNewswire)
Apr-12-23 07:20AM	Shareholders in Fate Therapeutics (NASDAQ:FATE) are in the red if they invested a year ago (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report? (Zacks)
Mar-27-23 09:00AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Mar-03-23 04:01PM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Mar-02-23 09:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:30AM	Fate Therapeutics Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-01-23 09:59AM	FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Feb-28-23 05:15PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-27-23 09:31AM	Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More (Zacks)
Feb-13-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-06-23 09:55AM	Wall Street Analysts Believe Fate Therapeutics (FATE) Could Rally 172.49%: Here's is How to Trade (Zacks)
Feb-02-23 09:46AM	GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities (GlobeNewswire) +7.22%
Jan-30-23 07:33AM	Calculating The Fair Value Of Fate Therapeutics, Inc. (NASDAQ:FATE) (Simply Wall St.)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xu Yuan	Director	Aug 06 '24	Sale	4.23	633	2,678	8,669	Aug 07 04:01 PM
Xu Yuan	Director	Aug 06 '24	Proposed Sale	4.23	633	2,678		Aug 06 10:34 AM
Dulac Edward J III	Chief Financial Officer	Mar 04 '24	Sale	7.77	2,447	19,013	101,479	Mar 05 04:24 PM
Dulac Edward J III	Chief Financial Officer	Jan 29 '24	Sale	5.00	1,849	9,245	103,926	Jan 30 04:01 PM
TAHL CINDY	General Counsel and Secretary	Jan 09 '24	Sale	4.37	10,874	47,519	142,361	Jan 10 04:30 PM
Valamehr Bahram	Chief R&D Officer	Jan 09 '24	Sale	4.38	11,271	49,367	158,069	Jan 10 04:30 PM
Wolchko J Scott	President and CEO	Jan 09 '24	Sale	4.37	14,391	62,889	371,248	Jan 10 04:29 PM
Dulac Edward J III	Chief Financial Officer	Jan 09 '24	Sale	4.37	7,028	30,712	105,775	Jan 10 04:29 PM
Dulac Edward J III	Chief Financial Officer	Jan 02 '24	Sale	3.66	5,182	18,966	112,803	Jan 03 04:03 PM
Redmile Group, LLC	Director	Dec 26 '23	Buy	3.72	44,630	166,024	13,180,388	Dec 28 09:30 PM
Dulac Edward J III	Chief Financial Officer	Dec 18 '23	Sale	3.50	1,585	5,548	117,985	Dec 19 04:01 PM
TAHL CINDY	General Counsel and Secretary	Nov 09 '23	Sale	2.40	24,363	58,471	153,235	Nov 13 04:01 PM

Open in Screener

AUGX

Augmedix Inc

Sep 20 • 04:00PM ET

2.34

Dollar change +0.01
Percentage change 0.43	%

Healthcare • Health Information Services • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC WISE

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	1.51%	Shs Outstand	49.43M	Perf Week	0.43%
Market Cap	115.67M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	-37.85%	Shs Float	48.68M	Perf Month	3.08%
Income	-23.85M	PEG	-	EPS next Q	-0.14	Inst Own	81.69%	Short Float	2.71%	Perf Quarter	191.23%
Sales	51.58M	P/S	2.24	EPS this Y	-20.45%	Inst Trans	0.67%	Short Ratio	1.56	Perf Half Y	-44.94%
Book/sh	0.21	P/B	10.97	EPS next Y	3.77%	ROA	-48.91%	Short Interest	1.32M	Perf Year	-55.43%
Cash/sh	0.57	P/C	4.10	EPS next 5Y	-	ROE	-329.77%	52W Range	0.73 - 6.25	Perf YTD	-60.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	62.58%	ROI	-81.34%	52W High	-62.56%	Beta	0.25
Dividend TTM	-	Quick Ratio	1.66	Sales past 5Y	33.97%	Gross Margin	48.22%	52W Low	220.55%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	1.66	EPS Y/Y TTM	14.91%	Oper. Margin	-46.29%	RSI (14)	79.07	Volatility	0.43% 0.62%
Employees	1430	Debt/Eq	2.41	Sales Y/Y TTM	39.32%	Profit Margin	-46.23%	Recom	3.00	Target Price	2.35
Option/Short	Yes / Yes	LT Debt/Eq	1.80	EPS Q/Q	-37.18%	Payout	-	Rel Volume	0.20	Prev Close	2.33
Sales Surprise	0.20%	EPS Surprise	-20.03%	Sales Q/Q	26.75%	Earnings	Aug 12 AMC	Avg Volume	846.61K	Price	2.34
SMA20	1.15%	SMA50	10.24%	SMA200	-25.04%	Trades		Volume	167,830	Change	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-24	Downgrade	Lake Street	Buy → Hold
Jul-22-24	Downgrade	B. Riley Securities	Buy → Neutral	$3 → $2.35
May-14-24	Downgrade	Maxim Group	Buy → Hold	$5
May-14-24	Downgrade	Evercore ISI	Outperform → In-line	$5 → $1.50
Apr-03-24	Resumed	B. Riley Securities	Buy	$5.50
Dec-15-23	Initiated	Evercore ISI	In-line	$6

Aug-12-24 05:10PM	Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024 (GlobeNewswire)
Aug-06-24 07:00AM	Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024 (GlobeNewswire)
Jul-25-24 02:30AM	Is Augmedix, Inc. (AUGX) the Best One-Dollar Stock to Buy Right Now? (Insider Monkey)
Jul-22-24 06:29AM	Commure to acquire AI scribe Augmedix in $139M deal (Healthcare Dive)
04:55AM	Loading…
04:55AM	Commure signs agreement to acquire Augmedix in $139m deal (Hospital Management)
Jul-19-24 03:33PM	Why Is Augmedix (AUGX) Stock Up 150% Today? (InvestorPlace) +146.62%
07:00AM	Augmedix to Join Forces with Commure (GlobeNewswire)
Jul-15-24 11:40AM	Why Is Augmedix, Inc. (AUGX) the Best Penny Stock to Buy Under $1? (Insider Monkey)
Jun-25-24 06:33PM	Why Is Augmedix, Inc. (AUGX) the Most Popular AI Penny Stock Under $1? (Insider Monkey)
Jun-20-24 11:51AM	Generative AI is coming to the emergency room (Fortune)
07:00AM	Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments (GlobeNewswire)
Jun-04-24 07:00AM	Augmedix Reiterates Second Quarter and Full Year 2024 Outlook (GlobeNewswire) -7.62%
May-29-24 07:00AM	Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer (GlobeNewswire)
May-14-24 12:21PM	Q1 2024 Augmedix Inc Earnings Call (Thomson Reuters StreetEvents) -51.07%
09:19AM	Loading…
09:19AM	Maxim Downgrades Augmedix to Hold From Buy (MT Newswires)
08:34AM	Why Is Augmedix (AUGX) Stock Down 41% Today? (InvestorPlace)
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
03:05AM	Augmedix Inc (AUGX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-13-24 08:55PM	AUGX Stock Earnings: Augmedix Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.17%
04:03PM	Augmedix Delivers 40% Revenue Growth for First Quarter of 2024 (GlobeNewswire)
May-03-24 07:00AM	Augmedix to Participate in Upcoming Investor Conferences in May and June 2024 (GlobeNewswire)
Apr-30-24 07:00AM	Augmedix to Announce First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
Apr-25-24 04:05PM	Augmedix Awarded on Newsweek's World's Best Digital Health Companies 2024 List (GlobeNewswire)
Apr-24-24 07:00AM	Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments (GlobeNewswire)
Apr-19-24 06:00AM	3 Penny Stocks That Could Make a Big Comeback by the End of Q2 (InvestorPlace)
Apr-12-24 02:05AM	Insider Sell: Augmedix Inc's (AUGX) Chief Strategy Officer Ian Shakil Sells 92,787 Shares (GuruFocus.com)
Apr-10-24 01:51AM	Augmedix Inc (AUGX) Chief Strategy Officer Ian Shakil Sells 89,167 Shares (GuruFocus.com) -5.17%
Apr-09-24 07:00AM	Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care (GlobeNewswire)
Apr-05-24 02:42AM	Augmedix Inc (AUGX) Chief Strategy Officer Ian Shakil Sells 109,961 Shares (GuruFocus.com)
07:00AM	Loading…
Apr-04-24 07:00AM	Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide (GlobeNewswire)
01:56AM	Augmedix Inc (AUGX) Chief Strategy Officer Ian Shakil Sells 97,441 Shares (GuruFocus.com)
Apr-02-24 08:35AM	Should You Invest in Augmedix (AUGX)? (Insider Monkey)
Mar-20-24 10:13AM	Augmedix, Inc. (NASDAQ:AUGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 06:41AM	Q4 2023 Augmedix Inc Earnings Call (Thomson Reuters StreetEvents) +18.92%
Mar-18-24 08:53PM	AUGX Stock Earnings: Augmedix Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:31PM	Augmedix Inc (AUGX) Reports Strong Revenue Growth and Margin Expansion in Q4 and Full Year 2023 (GuruFocus.com)
04:01PM	Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023 (GlobeNewswire)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-12-24 07:00AM	Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go (GlobeNewswire)
Mar-08-24 07:00AM	Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 (GlobeNewswire)
Feb-27-24 07:00AM	Augmedix to Participate in Citizens JMP Technology Conference (GlobeNewswire)
Feb-13-24 07:00AM	Augmedix Names Tomer Levy as New Senior Vice President of Engineering (GlobeNewswire)
Jan-22-24 04:15PM	Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET (GlobeNewswire)
Jan-16-24 07:00AM	Augmedix Announces Participation in Maxim Group Virtual Healthcare IT Investor Conference (GlobeNewswire)
Jan-05-24 08:00AM	Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue (GlobeNewswire)
Dec-22-23 07:00AM	7 Micro-Cap Stocks for Risk-Tolerant Investors to Buy in 2024 (InvestorPlace)
Dec-13-23 10:29AM	Augmedix Partners with Google Cloud to Bring Medically-Tuned AI Technology to Ambient Documentation (PR Newswire)
Nov-21-23 07:00AM	Augmedix Announces Closing of Public Offering of Common Stock, Including Additional Investments from HCA Healthcare and Redmile Group (GlobeNewswire)
Nov-16-23 08:51AM	Why Is Augmedix (AUGX) Stock Down 27% Today? (InvestorPlace) -17.31%
12:15AM	Augmedix Announces Pricing of Upsized Public Offering of 6,250,000 Shares of Common Stock (GlobeNewswire)
Nov-15-23 04:02PM	Augmedix Announces Proposed Public Offering of 5,500,000 Shares of Common Stock (GlobeNewswire)
Nov-10-23 09:55AM	How Much Upside is Left in Augmedix, Inc. (AUGX)? Wall Street Analysts Think 36.67% (Zacks)
08:50AM	Augmedix, Inc. (AUGX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Nov-07-23 09:55AM	Augmedix, Inc. (NASDAQ:AUGX) Q3 2023 Earnings Call Transcript (Insider Monkey) +13.19%
Nov-06-23 05:10PM	Augmedix Inc (AUGX) Reports 50% Revenue Growth and Expanded Gross Margins in Q3 2023 (GuruFocus.com) -6.57%
04:02PM	Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023 (GlobeNewswire)
Oct-30-23 07:00AM	Augmedix to Announce Third Quarter 2023 Financial Results and Host Investor Conference Call on November 6, 2023 (GlobeNewswire)
Oct-20-23 08:02AM	Definitive Healthcare Corp. (DH) Soars 7.1%: Is Further Upside Left in the Stock? (Zacks) -5.02%
Oct-12-23 07:59AM	Augmedix, Inc. (AUGX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks) -7.37%
Oct-09-23 08:50AM	Augmedix, Inc. (AUGX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Oct-05-23 07:15AM	Ellipsis Health and Augmedix to Partner to Bring Automated Mental Health Screenings to Patient Visits (PR Newswire)
07:00AM	Augmedix Forging Strategic Partnerships for an Open Network of Digital Health Solutions (GlobeNewswire)
Sep-27-23 07:00AM	Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician-Controlled Mobile App (GlobeNewswire)
Sep-25-23 07:54AM	Zacks.com featured highlights include Lifeway Foods, Augmedix and Clearwater Analytics (Zacks)
Sep-22-23 06:39AM	3 Best Breakout Stocks to Buy Now for Solid Returns (Zacks)
Sep-21-23 08:50AM	Augmedix, Inc. (AUGX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
07:00AM	Augmedix Announces Inaugural AI Advisory Council Members (GlobeNewswire)
Sep-20-23 07:22AM	Zacks Industry Outlook Highlights P3 Health Partners, Talkspace and Augmedix (Zacks)
Sep-12-23 09:40AM	Are Medical Stocks Lagging Augmedix (AUGX) This Year? (Zacks)
Sep-06-23 07:00AM	Augmedix Announces Expanding Coverage in Behavioral Health Field for Acute and Ambulatory Care Settings (GlobeNewswire)
Sep-05-23 08:50AM	Recent Price Trend in Augmedix, Inc. (AUGX) is Your Friend, Here's Why (Zacks)
Sep-04-23 09:55AM	Can Augmedix, Inc. (AUGX) Climb 36.06% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-24-23 09:40AM	Is Artivion (AORT) Outperforming Other Medical Stocks This Year? (Zacks) -9.23%
07:00AM	Augmedix Achieves HITRUST Certification to Further Mitigate Risk in Third-Party Privacy, Security and Compliance (GlobeNewswire)
Aug-18-23 07:00AM	Augmedix Announces Participation in Upcoming Investor Conferences in September 2023 (GlobeNewswire) +6.91%
Aug-16-23 09:55AM	Wall Street Analysts See a 32.11% Upside in Augmedix, Inc. (AUGX): Can the Stock Really Move This High? (Zacks)
08:50AM	Augmedix, Inc. (AUGX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Aug-09-23 09:25AM	Augmedix, Inc. (NASDAQ:AUGX) Q2 2023 Earnings Call Transcript (Insider Monkey) -5.54%
Aug-08-23 03:27PM	Why Shares of Augmedix Are Climbing on Tuesday (Motley Fool) +19.66%
Aug-07-23 05:50PM	Augmedix, Inc. (AUGX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Augmedix Delivers 47% Revenue Growth and Expanded Gross Margins for Second Quarter of 2023 (GlobeNewswire)
Jul-28-23 07:00AM	Augmedix to Announce Second Quarter 2023 Financial Results and Host Investor Conference Call on August 7, 2023 (GlobeNewswire)
Jul-12-23 08:29AM	Oceania Cruises Curates a Collection of Enticing Mediterranean Sojourns Sailing to Cosmopolitan Cities and Undiscovered Gems (PR Newswire)
Jul-10-23 08:42AM	Zacks Industry Outlook Highlights Definitive Healthcare, Clover Health and Augmedix (Zacks) -7.68%
Jul-07-23 11:04AM	3 Medical Info Systems Stocks to Consider From a Prospering Industry (Zacks)
Jun-29-23 08:50AM	Here's Why Momentum in Augmedix, Inc. (AUGX) Should Keep going (Zacks)
Jun-16-23 09:40AM	Is Augmedix (AUGX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-14-23 07:05AM	Augmedix Extends Term Loan Facility and Finalizes Terms for Equity Line of Credit (GlobeNewswire)
Jun-12-23 07:00AM	Augmedix Establishes AI Advisory Council to Guide the Companys Continued Development of High Standard, Responsible Product Development (GlobeNewswire) +9.20%
May-31-23 09:40AM	Is Augmedix (AUGX) Outperforming Other Medical Stocks This Year? (Zacks)
May-19-23 08:24AM	Augmedix Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-12-23 08:15AM	Augmedix, Inc. (AUGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -19.14%
07:00AM	Augmedix Delivers Continued Sales Momentum; Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-08-23 07:00AM	Augmedix to Announce First Quarter 2023 Financial Results and Host Investor Conference Call on May 12, 2023 (GlobeNewswire)
May-05-23 01:34PM	3 Must-Watch Wearable Tech Stocks as the Industry Booms (InvestorPlace) +15.62%
Apr-28-23 06:47PM	Dlocal, Augmedix See Activist Investor Action (Barrons.com)
06:47PM	Dlocal and Augmedix Stock See Action From Activist Investors (Barrons.com)
Apr-20-23 06:31AM	Augmedix Announces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation (GlobeNewswire) +88.89%
06:30AM	Augmedix Secures Strategic Financing from HCA Healthcare and Redmile Group (GlobeNewswire)

Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chatterjee Saurav	CHIEF TECHNOLOGY OFFICER	May 15 '24	Sale	1.19	1,767	2,103	2,921	May 17 09:00 PM
Shakil Ian	CHIEF STRATEGY OFFICER	May 15 '24	Sale	1.19	1,387	1,651	5,363	May 17 09:00 PM
Ginocchio Paul	CHIEF FINANCIAL OFFICER	May 15 '24	Sale	1.19	2,354	2,801	131,896	May 17 09:00 PM
Hawkins Jonathan	CHIEF REVENUE OFFICER	May 15 '24	Sale	1.19	1,767	2,103	2,921	May 17 09:00 PM
Krakaris Emmanuel	PRESIDENT, CEO, AND SECRETARY	May 15 '24	Sale	1.19	3,528	4,198	58,898	May 17 09:00 PM
Breber Sandra	CHIEF OPERATING OFFICER	May 15 '24	Sale	1.19	2,354	2,801	16,396	May 17 09:00 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 15 '24	Option Exercise	0.86	500	430	3,500	Apr 16 09:07 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 15 '24	Sale	3.80	500	1,900	3,000	Apr 16 09:07 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 12 '24	Option Exercise	0.86	19,544	16,808	22,544	Apr 15 09:15 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 12 '24	Sale	3.82	19,544	74,590	3,000	Apr 15 09:15 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 10 '24	Option Exercise	0.86	36,467	31,362	39,467	Apr 11 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 09 '24	Option Exercise	0.76	31,542	23,968	34,542	Apr 11 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 11 '24	Option Exercise	0.86	24,778	21,309	27,778	Apr 11 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 10 '24	Sale	3.87	36,467	141,288	3,000	Apr 11 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 09 '24	Sale	4.14	31,542	130,521	3,000	Apr 11 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 11 '24	Sale	3.93	24,778	97,477	3,000	Apr 11 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 08 '24	Option Exercise	0.64	28,563	18,280	40,780	Apr 09 08:49 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 05 '24	Sale	4.03	51,387	207,233	12,217	Apr 09 08:49 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 08 '24	Sale	3.97	37,780	149,968	3,000	Apr 09 08:49 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 04 '24	Sale	4.15	64,055	265,854	31,610	Apr 04 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 03 '24	Sale	4.11	45,906	188,600	95,665	Apr 04 08:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 01 '24	Option Exercise	0.64	51,346	32,861	239,012	Apr 03 09:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 01 '24	Sale	3.91	58,978	230,384	180,034	Apr 03 09:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Apr 02 '24	Sale	3.89	38,463	149,725	141,571	Apr 03 09:30 PM
Shakil Ian	CHIEF STRATEGY OFFICER	Mar 28 '24	Sale	4.06	31,994	129,851	187,666	Apr 01 08:28 PM
Ginocchio Paul	CHIEF FINANCIAL OFFICER	Nov 22 '23	Buy	4.85	10,000	48,500	128,000	Nov 27 07:00 AM
Redmile Group, LLC	Director	Nov 20 '23	Buy	4.00	750,000	3,000,000	16,404,017	Nov 22 04:15 PM
Redmile Group, LLC	Director	Nov 20 '23	Buy	4.00	750,000	3,000,000	9,446,146	Nov 22 04:15 PM

Open in Screener

IGMS

IGM Biosciences Inc

Sep 20 • 04:00PM ET

16.16

Dollar change -1.07
Percentage change -6.21	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

IGMS IGM Biosciences Inc daily Stock Chart

Held by: IWM VTI VXF IWO SCHA VTWO IWC VHT IWN CNCR

Index	RUT	P/E	-	EPS (ttm)	-3.68	Insider Own	64.79%	Shs Outstand	33.18M	Perf Week	31.38%
Market Cap	958.61M	Forward P/E	-	EPS next Y	-2.86	Insider Trans	0.94%	Shs Float	20.89M	Perf Month	48.80%
Income	-220.40M	PEG	-	EPS next Q	-0.79	Inst Own	37.40%	Short Float	26.51%	Perf Quarter	121.37%
Sales	2.91M	P/S	329.42	EPS this Y	33.78%	Inst Trans	-0.70%	Short Ratio	17.77	Perf Half Y	57.97%
Book/sh	2.07	P/B	7.82	EPS next Y	8.23%	ROA	-53.94%	Short Interest	5.54M	Perf Year	131.85%
Cash/sh	4.33	P/C	3.73	EPS next 5Y	-	ROE	-115.71%	52W Range	3.81 - 22.50	Perf YTD	94.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.65%	ROI	-141.47%	52W High	-28.18%	Beta	0.17
Dividend TTM	-	Quick Ratio	7.06	Sales past 5Y	19.85%	Gross Margin	-205.46%	52W Low	324.15%	ATR (14)	1.79
Dividend Ex-Date	-	Current Ratio	7.06	EPS Y/Y TTM	30.22%	Oper. Margin	-8137.82%	RSI (14)	67.91	Volatility	24.70% 13.34%
Employees	224	Debt/Eq	0.32	Sales Y/Y TTM	74.00%	Profit Margin	-7571.35%	Recom	1.67	Target Price	23.88
Option/Short	Yes / Yes	LT Debt/Eq	0.27	EPS Q/Q	44.48%	Payout	-	Rel Volume	1.92	Prev Close	17.23
Sales Surprise	-97.69%	EPS Surprise	-1841.03%	Sales Q/Q	179.91%	Earnings	Aug 14 BMO	Avg Volume	311.52K	Price	16.16
SMA20	36.69%	SMA50	49.84%	SMA200	64.04%	Trades		Volume	597,969	Change	-6.21%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $21
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$8
Dec-07-23	Downgrade	H.C. Wainwright	Buy → Neutral	$11 → $7
Nov-09-22	Resumed	Jefferies	Buy	$61 → $55
Oct-17-22	Initiated	JP Morgan	Neutral	$27
Aug-29-22	Initiated	BofA Securities	Buy	$34
Dec-13-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$51
Nov-05-21	Upgrade	Wedbush	Neutral → Outperform
Aug-26-21	Initiated	Morgan Stanley	Overweight	$100
Jan-29-21	Initiated	RBC Capital Mkts	Outperform	$121
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$88 → $114
Dec-22-20	Downgrade	Wedbush	Outperform → Neutral
Jul-17-20	Initiated	Robert W. Baird	Outperform	$90
Jul-01-20	Initiated	H.C. Wainwright	Buy	$88
May-28-20	Initiated	SunTrust	Buy	$86
Apr-22-20	Initiated	Wedbush	Outperform	$73
Oct-14-19	Initiated	Stifel	Buy	$32
Oct-14-19	Initiated	Piper Jaffray	Overweight	$26
Oct-14-19	Initiated	Jefferies	Buy	$25
Oct-14-19	Initiated	Guggenheim	Buy	$30

Show Previous Ratings

Sep-18-24 09:33AM	IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? (Zacks) -5.83%
Sep-10-24 04:05PM	IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit (GlobeNewswire) +9.74%
Aug-22-24 12:00PM	All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy (Zacks)
Aug-14-24 08:00AM	IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
09:35AM	Loading…
Jul-12-24 09:35AM	IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock? (Zacks)
May-29-24 07:00AM	IGM Biosciences to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-10-24 02:38PM	IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ... (GuruFocus.com) -7.71%
May-09-24 07:38AM	RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk (MT Newswires) +8.35%
May-08-24 10:55PM	IGMS Stock Earnings: IGM Biosciences Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.94%
05:55PM	IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:10PM	IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 07:00AM	IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference (GlobeNewswire)
May-03-24 10:00AM	IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) +6.79%
Apr-30-24 12:00PM	IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:30AM	Loading…
Apr-17-24 08:30AM	IGM Biosciences Announces Refocusing of Sanofi Collaboration (GlobeNewswire) -11.63%
Apr-10-24 07:00AM	IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum (GlobeNewswire) -6.41%
Mar-07-24 10:52PM	IGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:45PM	IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:10PM	IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-01-24 09:55AM	Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet (Zacks)
Feb-14-24 09:55AM	Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade (Zacks)
Feb-01-24 07:00AM	IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +8.17%
Jan-16-24 08:38AM	IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why (Zacks) -12.89%
Jan-03-24 07:00AM	IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-23 04:09AM	15 Best Falling Stocks To Buy Now (Insider Monkey) -5.00%
Dec-06-23 02:44AM	Medivir to present at the Carlsquare Equity Research Investor Day (PR Newswire)
Dec-05-23 04:01PM	IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension (GlobeNewswire) +9.17%
Dec-01-23 05:32AM	Bulletin from Extraordinary General Meeting in Medivir AB (publ) (PR Newswire) -7.79%
Nov-27-23 03:52AM	Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC (PR Newswire)
02:46AM	Loading…
Nov-22-23 02:46AM	Medivir to present at the Redeye Life Science Day (PR Newswire)
Nov-21-23 02:48AM	Medivir to present at the Erik Penser Bank Company Event (PR Newswire)
Nov-16-23 09:55AM	Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect? (Zacks)
Nov-14-23 07:28PM	IGM Biosciences Inc (IGMS) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com) +21.90%
Nov-13-23 04:10PM	IGM Biosciences Announces Third Quarter 2023 Financial Results (GlobeNewswire)
03:49AM	Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA (PR Newswire)
Nov-07-23 07:00AM	IGM Biosciences to Present at Two Upcoming Investor Conferences (GlobeNewswire) +10.43%
Oct-25-23 02:46AM	Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday (PR Newswire)
Oct-23-23 02:48AM	Nomination Committee of Medivir appointed (PR Newswire)
Oct-20-23 09:29AM	Change in Medivir's Board of Directors (PR Newswire)
Oct-05-23 07:29AM	Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles (PR Newswire) +7.26%
Oct-03-23 04:05PM	IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors (GlobeNewswire) -7.06% -10.66%
Sep-20-23 04:36AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-06-23 07:00AM	IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-10-23 08:59PM	Down More Than 50%: These 2 Strong Buy Stocks Are Too Cheap to Ignore (TipRanks)
Aug-03-23 05:25PM	IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:10PM	IGM Biosciences Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-05-23 06:46AM	Daily Vickers Top Buyers & Sellers for 07/05/2023 (Argus Research)
Jul-03-23 04:01PM	IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-23 09:48AM	While hedge funds own 27% of IGM Biosciences, Inc. (NASDAQ:IGMS), individual investors are its largest shareholders with 28% ownership (Simply Wall St.)
Jun-22-23 08:14PM	Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength? (Zacks) +7.62%
07:58AM	IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement (GlobeNewswire)
Jun-21-23 05:17PM	IGM Announces Proposed Public Offering and Concurrent Private Placement (GlobeNewswire) -5.50%
Jun-02-23 05:30PM	IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development (GlobeNewswire) +5.92% -22.13%
Jun-01-23 07:00AM	IGM Biosciences to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.56%
May-31-23 07:00AM	IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis (GlobeNewswire)
May-30-23 07:00AM	IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update (GlobeNewswire)
May-25-23 11:58AM	Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation (Simply Wall St.)
May-12-23 10:15AM	IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
09:05AM	IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 07:00AM	IGM Biosciences to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Apr-28-23 11:50AM	Bullish IGM Biosciences, Inc. (NASDAQ:IGMS) insiders filled their treasuries with US$1.6m worth of stock over last year (Simply Wall St.)
Apr-19-23 07:00AM	IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days (GlobeNewswire)
Apr-13-23 04:05PM	IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023 (GlobeNewswire) +14.63%
Apr-06-23 12:23PM	IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-01-23 09:17AM	Further weakness as IGM Biosciences (NASDAQ:IGMS) drops 11% this week, taking three-year losses to 77% (Simply Wall St.)
Mar-30-23 06:05PM	IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -19.27%
04:05PM	IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-23 07:00AM	IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023 (GlobeNewswire) +6.70%
Feb-02-23 07:00AM	IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference (GlobeNewswire) +9.67%
Jan-17-23 07:00AM	IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors (GlobeNewswire)
Jan-09-23 07:00AM	IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development (GlobeNewswire) +8.66%
Jan-03-23 07:00AM	IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-22 10:00AM	IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-01-22 07:00AM	IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference (GlobeNewswire)
Nov-16-22 06:37AM	The Independent Director of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Just Bought 27% More Shares (Simply Wall St.)
Nov-08-22 07:00AM	IGM Biosciences to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-03-22 10:25AM	IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.46%
09:05AM	IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 04:05PM	IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkins Lymphoma (GlobeNewswire)
Oct-27-22 02:06PM	Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation (Simply Wall St.)
Sep-06-22 07:00AM	IGM Biosciences to Present at Three Upcoming Investor Conferences (GlobeNewswire) -5.77%
Aug-08-22 06:45PM	IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +9.77% +11.31%
04:10PM	IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-04-22 02:04PM	IGM Biosciences, Inc. (NASDAQ:IGMS) insiders placed bullish bets worth US$2.3m in the last 12 months (Simply Wall St.)
Jun-01-22 07:00AM	IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-20-22 12:07PM	We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate (Simply Wall St.)
May-10-22 07:00AM	IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.34%
May-09-22 04:16PM	IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -12.23%
May-06-22 07:00AM	IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi (GlobeNewswire)
Apr-09-22 09:35AM	Nielsen, IGM Biosciences, and, Yes, Twitter, See Action From Activist Investors (Barrons.com)
Apr-06-22 04:39PM	IGM Announces Closing of $230.0 Million Public Offering (GlobeNewswire) +8.33% -8.47%
Apr-05-22 04:56PM	What Kind Of Investors Own Most Of IGM Biosciences, Inc. (NASDAQ:IGMS)? (Simply Wall St.)
Mar-30-22 03:06PM	Why Did Truist Lower IGM Biosciences' Price Target? (Benzinga) -12.34%
02:14PM	Is IGM Biosciences Stock a Buy Following Sanofi Deal Surge? RBC Weighs In (TipRanks)
01:29PM	Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More (Zacks)
11:57AM	IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi (Zacks)
12:56AM	IGM Announces Pricing of $200.0 Million Public Offering (GlobeNewswire)
Mar-29-22 11:41AM	Why IGM Biosciences Stock Rocketed Higher Today (Motley Fool) +96.73%
09:00AM	These 2 Stocks Are Up 20%-Plus in Tuesday's Premarket (Motley Fool)

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Sep 13 '24	Sale	11.54	469	5,412	25,543	Sep 17 08:58 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Sep 13 '24	Sale	11.54	1,487	17,158	154,331	Sep 17 08:55 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Sep 13 '24	Sale	11.54	1,487	17,158	122,694	Sep 17 08:54 PM
Schwarzer Fred	CEO AND PRESIDENT	Sep 13 '24	Sale	11.54	3,946	45,532	250,124	Sep 17 08:52 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Sep 13 '24	Sale	11.54	1,487	17,158	242,948	Sep 17 08:50 PM
Harler Mary Beth	Head, Research & Autoimmunity	Sep 13 '24	Sale	11.54	1,487	17,158	163,740	Sep 17 08:44 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Sep 13 '24	Sale	11.54	925	10,673	79,104	Sep 17 08:42 PM
Hambleton Julie	Director	Jul 25 '24	Option Exercise	1.39	15,132	21,033	17,132	Jul 29 05:45 PM
Hambleton Julie	Director	Jul 25 '24	Sale	14.00	15,132	211,848	2,000	Jul 29 05:45 PM
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Jun 14 '24	Sale	7.58	495	3,750	26,012	Jun 18 07:45 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Jun 14 '24	Sale	7.58	1,570	11,893	95,818	Jun 18 07:44 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Jun 14 '24	Sale	7.58	1,570	11,893	88,848	Jun 18 07:43 PM
Schwarzer Fred	CEO AND PRESIDENT	Jun 14 '24	Sale	7.58	4,164	31,544	254,070	Jun 18 07:42 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Jun 14 '24	Sale	7.58	1,106	8,378	197,769	Jun 18 07:41 PM
Harler Mary Beth	Head, Research & Autoimmunity	Jun 14 '24	Sale	7.58	1,570	11,893	85,227	Jun 18 07:40 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Jun 14 '24	Sale	7.58	977	7,401	60,029	Jun 18 07:38 PM
BAKER BROS. ADVISORS LP	Director	Mar 26 '24	Buy	8.26	270,000	2,230,767	3,638,533	Mar 28 07:04 PM
BAKER BROS. ADVISORS LP	Director	Mar 28 '24	Buy	9.62	97,473	937,632	3,753,480	Mar 28 07:04 PM
BAKER BROS. ADVISORS LP	Director	Mar 27 '24	Buy	9.24	27,844	257,170	3,664,073	Mar 28 07:04 PM
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Mar 13 '24	Sale	9.88	529	5,224	26,971	Mar 15 07:57 PM
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Mar 14 '24	Sale	10.17	464	4,719	26,507	Mar 15 07:57 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Mar 13 '24	Sale	9.88	2,889	28,529	96,923	Mar 15 07:55 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Mar 14 '24	Sale	10.17	2,535	25,782	94,388	Mar 15 07:55 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Mar 13 '24	Sale	9.88	2,897	28,608	92,961	Mar 15 07:53 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Mar 14 '24	Sale	10.17	2,543	25,864	90,418	Mar 15 07:53 PM
Schwarzer Fred	CEO AND PRESIDENT	Mar 13 '24	Sale	9.88	4,765	47,055	220,833	Mar 15 07:51 PM
Schwarzer Fred	CEO AND PRESIDENT	Mar 14 '24	Sale	10.17	4,182	42,533	216,651	Mar 15 07:51 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Mar 13 '24	Sale	9.88	2,101	20,748	173,700	Mar 15 07:49 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Mar 14 '24	Sale	10.17	1,844	18,754	171,856	Mar 15 07:49 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Mar 13 '24	Sale	9.88	1,798	17,756	62,584	Mar 15 07:48 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Mar 14 '24	Sale	10.17	1,578	16,049	61,006	Mar 15 07:48 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Mar 01 '24	Option Exercise	0.93	3,026	2,814	4,039	Mar 05 07:34 PM
Schwarzer Fred	CEO and President	Dec 13 '23	Sale	5.78	17,576	101,558	102,848	Dec 15 07:20 PM
Keyt Bruce	Chief Scientific Officer	Dec 13 '23	Sale	5.78	7,574	43,764	129,551	Dec 15 07:19 PM
Decker Lisa Lynn	Chief Business Officer	Dec 13 '23	Sale	5.78	4,369	25,245	35,632	Dec 15 07:18 PM
BAKER BROS. ADVISORS LP	Director	Dec 15 '23	Buy	6.55	288,007	1,887,531	3,390,323	Dec 15 05:32 PM
BAKER BROS. ADVISORS LP	Director	Dec 14 '23	Buy	6.50	157,370	1,023,157	3,123,585	Dec 15 05:32 PM
BAKER BROS. ADVISORS LP	Director	Dec 13 '23	Buy	5.96	87,316	520,776	2,977,836	Dec 15 05:32 PM
Takimoto Chris H	Chief Medical Officer	Nov 29 '23	Sale	6.21	1,180	7,331	53,562	Dec 01 07:03 PM
Gauthier George	Chief Commercial Officer	Nov 29 '23	Sale	6.21	1,180	7,331	39,642	Dec 01 07:02 PM
Decker Lisa Lynn	Chief Business Officer	Nov 29 '23	Sale	6.21	1,180	7,331	40,001	Dec 01 07:01 PM
Tahir Misbah	Chief Financial Officer	Nov 27 '23	Sale	5.06	1,337	6,764	49,608	Nov 29 08:49 PM
Schwarzer Fred	CEO and President	Nov 27 '23	Sale	5.06	1,337	6,764	120,424	Nov 29 08:48 PM
Keyt Bruce	Chief Scientific Officer	Nov 27 '23	Sale	5.06	933	4,720	137,125	Nov 29 08:47 PM
Gauthier George	Chief Commercial Officer	Oct 02 '23	Sale	7.95	935	7,430	39,082	Oct 03 07:55 PM

Open in Screener

ZYME

Zymeworks BC Inc

Sep 20 • 04:00PM ET

13.09

Dollar change +0.04
Percentage change 0.31	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM IWN IBB BSVO VTWO DFAC VHT IWC EES

Index	RUT	P/E	-	EPS (ttm)	-1.52	Insider Own	2.72%	Shs Outstand	70.12M	Perf Week	4.39%
Market Cap	937.51M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	0.00%	Shs Float	69.67M	Perf Month	17.93%
Income	-112.51M	PEG	-	EPS next Q	-0.40	Inst Own	96.31%	Short Float	6.04%	Perf Quarter	55.65%
Sales	62.71M	P/S	14.95	EPS this Y	35.59%	Inst Trans	-0.51%	Short Ratio	6.02	Perf Half Y	22.91%
Book/sh	5.69	P/B	2.30	EPS next Y	-4.69%	ROA	-20.13%	Short Interest	4.21M	Perf Year	97.14%
Cash/sh	4.61	P/C	2.84	EPS next 5Y	11.00%	ROE	-26.32%	52W Range	6.01 - 13.14	Perf YTD	25.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.52%	ROI	-26.57%	52W High	-0.38%	Beta	1.19
Dividend TTM	-	Quick Ratio	7.01	Sales past 5Y	264.10%	Gross Margin	76.51%	52W Low	117.62%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	7.01	EPS Y/Y TTM	-154.13%	Oper. Margin	-191.47%	RSI (14)	77.12	Volatility	3.75% 3.71%
Employees	277	Debt/Eq	0.05	Sales Y/Y TTM	-85.99%	Profit Margin	-179.42%	Recom	1.86	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	35.12%	Payout	-	Rel Volume	1.06	Prev Close	13.05
Sales Surprise	61.22%	EPS Surprise	-17.37%	Sales Q/Q	174.82%	Earnings	Aug 01 AMC	Avg Volume	699.36K	Price	13.09
SMA20	10.07%	SMA50	19.70%	SMA200	29.09%	Trades		Volume	742,271	Change	0.31%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-23	Resumed	Wells Fargo	Overweight	$12
Jan-04-23	Reiterated	H.C. Wainwright	Neutral	$10 → $8
Dec-20-22	Upgrade	Jefferies	Hold → Buy	$7.70 → $11
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral	$40 → $8
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$8
Oct-04-22	Resumed	Wells Fargo	Overweight	$45 → $9
May-05-22	Upgrade	Guggenheim	Neutral → Buy	$14
Mar-15-22	Initiated	Evercore ISI	Outperform	$15
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold	$32
Mar-31-21	Initiated	Credit Suisse	Outperform	$55
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$41
Feb-08-21	Resumed	H.C. Wainwright	Buy	$57
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$50 → $53
Sep-29-20	Resumed	JP Morgan	Neutral	$48
Aug-06-20	Initiated	SVB Leerink	Outperform	$45
Jan-10-20	Initiated	Wolfe Research	Outperform	$61
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy	$65

Show Previous Ratings

Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-18-24 06:00AM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference (GlobeNewswire)
Sep-03-24 04:30PM	Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) (GlobeNewswire)
Aug-22-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 04:10PM	Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock (GlobeNewswire)
04:05PM	Loading…
04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-24 04:30PM	Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer (GlobeNewswire)
Jul-22-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor- Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate (GlobeNewswire)
Jul-11-24 06:30AM	Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 (GlobeNewswire) +6.82%
Jun-17-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers (GlobeNewswire) -5.53%
Jun-10-24 06:00AM	Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer (GlobeNewswire)
May-28-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm (GlobeNewswire)
May-16-24 04:20PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME) (Business Wire)
04:05PM	Loading…
May-02-24 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Apr-11-24 06:00AM	Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Apr-10-24 09:35AM	Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-08-24 06:00AM	Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-28-24 06:00AM	Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors (GlobeNewswire)
Mar-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-22-24 12:00PM	Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-11-24 12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-07-24 06:39AM	Zymeworks halts plans for phase 2 ADC trial to mull 'evolving clinical landscape' (FierceBiotech.com) -6.46%
Mar-06-24 10:53PM	ZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:09PM	Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:30PM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for (Zacks) -6.51%
06:00AM	Loading…
Feb-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 06:00AM	Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call (GlobeNewswire)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Feb-08-24 06:00AM	Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors (GlobeNewswire)
Jan-31-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-11-24 12:00PM	Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know (Zacks)
Jan-04-24 06:15AM	Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 (GlobeNewswire)
06:00AM	Zymeworks Announces Additional Leadership Appointments (GlobeNewswire)
Dec-26-23 08:00AM	Zymeworks Announces $50 Million Private Placement to EcoR1 Capital (GlobeNewswire) +8.65%
Dec-15-23 08:30AM	Zymeworks Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-08-23 10:11AM	5 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Nov-30-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Nov-08-23 05:33PM	Zymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-17-23 08:30AM	Zymeworks To Host Third Quarter 2023 Results Conference Call (GlobeNewswire)
Oct-16-23 04:30PM	Zymeworks Announces New Director Nominee (GlobeNewswire) +8.46%
Aug-10-23 04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -7.60%
Aug-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-19-23 08:30AM	Zymeworks To Host Second Quarter 2023 Results Conference Call (GlobeNewswire)
Jul-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Jun-29-23 04:05PM	Zymeworks Appoints New Director (GlobeNewswire)
Jun-26-23 08:30AM	Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes (GlobeNewswire)
Jun-02-23 06:41PM	Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers (PR Newswire)
Jun-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-18-23 08:30AM	Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer (GlobeNewswire)
May-08-23 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) +12.79%
May-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Apr-18-23 04:05PM	Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-17-23 08:30AM	Zymeworks To Host First Quarter 2023 Results Conference Call (Business Wire)
Apr-10-23 08:30AM	Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors (Business Wire)
Apr-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Mar-14-23 04:30PM	Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-07-23 04:05PM	Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-28-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Feb-21-23 08:30AM	Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call (Business Wire)
Jan-25-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Jan-19-23 07:45AM	Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma (PR Newswire)
Jan-04-23 04:15PM	Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 (Business Wire)
Dec-21-22 07:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (Business Wire) +23.59%
07:30AM	Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab (PR Newswire)
Dec-19-22 07:00AM	Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab (Business Wire) +5.11%
Dec-14-22 04:15PM	Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (Business Wire)
Dec-09-22 08:00AM	New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS (Business Wire) -5.23%
Dec-05-22 08:30AM	Zymeworks to Transfer Stock Listing to Nasdaq (Business Wire)
Nov-29-22 08:30AM	Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals (Business Wire)
Nov-24-22 12:20PM	Why Zymeworks Inc. (ZYME) Might be Well Poised for a Surge (Zacks)
Nov-22-22 09:55AM	Wall Street Analysts Believe Zymeworks Inc. (ZYME) Could Rally 59%: Here's is How to Trade (Zacks)
08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (Business Wire)
Nov-21-22 12:22PM	Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option (Zacks)
09:55AM	Zymeworks Inc. (ZYME) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:00AM	Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) (Business Wire)
Nov-08-22 05:45PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:22PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-02-22 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.64%
Nov-01-22 10:01AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-31-22 04:42PM	Why Shares of Zymeworks Rose 12.18% on Monday (Motley Fool) +11.73%
Oct-21-22 01:35PM	Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline (Benzinga)
Oct-20-22 01:36PM	Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals (Zacks)
11:48AM	Zymeworks Inc. (ZYME) Surges 15.9%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms (Business Wire)
Oct-19-22 11:08AM	Why Zymeworks Stock Is Soaring Today (Motley Fool) +15.86%
08:38AM	Zymeworks, Jazz agree to licensing deal for cancer drug (MarketWatch)
07:29AM	Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal (Benzinga)
06:07AM	Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab (Business Wire)
06:00AM	Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody (PR Newswire)
Oct-18-22 08:30AM	Zymeworks to Host Third Quarter Results Conference Call (Business Wire)
Oct-13-22 07:00AM	Zymeworks Completes Plan to Become Delaware Corporation (Business Wire)
Oct-07-22 04:15PM	Zymeworks Announces Results of Special Meeting (Business Wire)
Oct-04-22 08:30AM	Zymeworks Reminds Shareholders to Vote FOR its Redomicile (Business Wire)

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Galbraith Kenneth	Chair & CEO	Jan 05 '24	Option Exercise	0.00	47,666	0	47,666	Jan 08 06:23 PM
Galbraith Kenneth	Chair & CEO	Jan 05 '24	Sale	10.65	18,198	193,849	29,468	Jan 08 06:23 PM
Galbraith Kenneth	Chair & CEO	Jan 08 '24	Sale	11.22	5,706	63,996	23,762	Jan 08 06:23 PM
Astle Christopher	SVP & Chief Financial Officer	Jan 05 '24	Option Exercise	0.00	10,500	0	12,497	Jan 08 06:14 PM
Astle Christopher	SVP & Chief Financial Officer	Jan 05 '24	Sale	10.65	4,563	48,606	7,934	Jan 08 06:14 PM
Astle Christopher	SVP & Chief Financial Officer	Jan 08 '24	Sale	11.22	1,431	16,050	6,503	Jan 08 06:14 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '24	Option Exercise	0.00	17,166	0	17,166	Jan 08 06:01 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '24	Sale	10.65	7,460	79,465	9,706	Jan 08 06:01 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 08 '24	Sale	11.22	2,339	26,233	7,367	Jan 08 06:01 PM
Astle Christopher	SVP & Chief Financial Officer	Dec 11 '23	Option Exercise	0.00	1,550	0	2,883	Dec 11 08:00 PM
Astle Christopher	SVP & Chief Financial Officer	Dec 11 '23	Sale	9.13	886	8,089	1,997	Dec 11 08:00 PM

ADCT

Adc Therapeutics SA

ABSI

Absci Corp

FATE

Fate Therapeutics Inc

AUGX

Augmedix Inc

IGMS

IGM Biosciences Inc

ZYME

Zymeworks BC Inc

Upgrade your FINVIZ experience